Cliff Asness's KYMR Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 9,339 shares of Kymera Therapeutics, Inc. (KYMR) worth $726,668, representing 0.00% of the portfolio. First purchased in 2024-Q3, this short-term holding has been held for 6 quarters.
Based on 13F filings, Cliff Asness has maintained this position in KYMR for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 8,083 shares. Largest reduction occurred in Q1 2025, reducing 6,576 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Kymera Therapeutics (KYMR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Kymera Therapeutics (KYMR) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +719 | Add 8.34% | 9,339 | $77.81 |
| Q3 2025 | +537 | Add 6.64% | 8,620 | $56.60 |
| Q2 2025 | +8,083 | New Buy | 8,083 | $43.64 |
| Q1 2025 | -6,576 | Sold Out | 0 | $0.00 |
| Q4 2024 | -5,684 | Reduce 46.36% | 6,576 | $40.23 |
| Q3 2024 | +12,260 | New Buy | 12,260 | $47.33 |
Cliff Asness's Kymera Therapeutics Investment FAQs
Cliff Asness first purchased Kymera Therapeutics, Inc. (KYMR) in Q3 2024, acquiring 12,260 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Kymera Therapeutics, Inc. (KYMR) for 6 quarters since Q3 2024.
Cliff Asness's largest addition to Kymera Therapeutics, Inc. (KYMR) was in Q3 2024, adding 12,260 shares worth $580,265.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 9,339 shares of Kymera Therapeutics, Inc. (KYMR), valued at approximately $726,668.
As of the Q4 2025 filing, Kymera Therapeutics, Inc. (KYMR) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Kymera Therapeutics, Inc. (KYMR) was 12,260 shares, as reported at the end of Q3 2024.